Your session is about to expire
← Back to Search
Platelet-rich Plasma
PRP for Eyebrow Hypotrichosis and Alopecia Areata
Phase 2
Recruiting
Led By Murad Alam
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is to test whether autologous platelet-rich plasma can help treat eyebrow hypotrichosis, or insufficient eyebrow hair growth. 40 people will be randomly chosen to either receive the plasma injections or a placebo saline solution. The trial will last 9 months.
Who is the study for?
This trial is for adults aged 18-85 in the Chicago area with mild to moderate eyebrow thinning who are healthy and can give informed consent. It's not for those with uncontrolled diseases affecting hair growth, recent use of certain hair growth drugs, significant blood disorders, genetic conditions impacting fibroblasts or collagen, pregnant/breastfeeding individuals, or those unable to follow the study protocol.
What is being tested?
The trial tests if injections of platelet-rich plasma (PRP) help people with sparse eyebrows compared to saline (saltwater) injections. About 40 participants will be randomly chosen to receive either PRP or saline over a period of nine months in this pilot study aimed at assessing procedure feasibility.
What are the potential side effects?
While specific side effects aren't listed here, common ones from similar procedures may include discomfort at injection sites, infection risk, bruising or bleeding especially in those with clotting disorders. The safety profile will be closely monitored throughout the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Platelet-Rich PlasmaExperimental Treatment1 Intervention
Participants will receive intradermal injections of 2-3mL autologous PRP to eyebrows.Three treatments will be performed 1 month apart.
Group II: Placebo (sterile saline)Placebo Group1 Intervention
Participants will receive intradermal injections of 2-3mL sterile saline to eyebrows.Three treatments will be performed 1 month apart.
Find a Location
Who is running the clinical trial?
Northwestern UniversityLead Sponsor
1,652 Previous Clinical Trials
961,485 Total Patients Enrolled
Murad AlamPrincipal Investigator - Northwestern University
Northwestern Memorial Hospital
Yale University School Of Medicine (Medical School)
Ny And Presby Hospital (Residency)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a medical condition that is not well controlled and could prevent your hair from growing properly.You have tattoos, scars, or dark spots on your eyebrows that may make it difficult to properly assess hair growth in that area.You are currently taking medication to thin your blood or prevent clotting.You have another skin condition in the treatment area that could make it difficult to assess the effectiveness of the treatment.You have thin eyebrows, but not too severe.You have low platelet count, problems with blood clotting, low levels of fibrinogen, anemia, cancer, active infections with specific bacteria, certain medical conditions related to hair, thyroid, eyes, skin, or immune system, or a history of certain infectious diseases.You have very thin eyebrows and want to make them thicker (Grade 3 or 4 according to the screening assessment).
Research Study Groups:
This trial has the following groups:- Group 1: Placebo (sterile saline)
- Group 2: Platelet-Rich Plasma
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.